<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014624</url>
  </required_header>
  <id_info>
    <org_study_id>CS747S-B-U4001</org_study_id>
    <nct_id>NCT01014624</nct_id>
  </id_info>
  <brief_title>Prasugrel/Clopidogrel Maintenance Dose Washout Study</brief_title>
  <official_title>Recovery of Platelet Function Following Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Subjects With Stable Coronary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to describe the cumulative proportion of participants&#xD;
      who return to baseline platelet P2Y12 receptor function over time (up to 12 days post last&#xD;
      maintenance dose) following discontinuation of prasugrel 10 mg daily x 7 days assessed by&#xD;
      Accumetrics VerifyNow P2Y12 reaction units (PRU) and described by Kaplan Meier curves. The&#xD;
      primary analysis is descriptive and is intended to provide information relating to the return&#xD;
      of baseline platelet function following discontinuation of maintenance therapy with either&#xD;
      prasugrel or clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition of Return to Baseline</measure>
    <time_frame>up to 12 days after last dose</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. The results are expressed as cumulative percentage of participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Secondary Definition of Return to Baseline</measure>
    <time_frame>up to 12 days after last dose</time_frame>
    <description>On the first day of the Washout Period (visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on Primary Definition of Return to Baseline Using the Primary Population</measure>
    <time_frame>up to 12 days after last dose</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participants met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on Secondary Definition of Return to Baseline Using the Primary Population</measure>
    <time_frame>up to 12 days after last dose</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on the Primary Definition of Return to Baseline Using the Responder Population</measure>
    <time_frame>up to 12 days after last dose</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on the Secondary Definition of Return to Baseline Using the Responder Population</measure>
    <time_frame>up to 12 days after the last dose</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to (&lt;=) 20%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Inhibition of Platelet Aggregation on Washout Day 1</measure>
    <time_frame>Washout Day 1</time_frame>
    <description>Inhibition of platelet aggregation was assessed by Accumetrics VerifyNowÂ® P2Y12 reaction units (PRU). On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Baseline PRU for the Primary Population Using the Primary Definition of Return to Baseline in Relation to the Inhibition of Platelet Aggregation 24 Hours Following the Last Maintenance Dose</measure>
    <time_frame>up to 12 days after the last dose</time_frame>
    <description>Time to return to baseline PRU (&lt;= 60 units of baseline) dependent upon baseline PRU and platelet % inhibition on Washout Period Day 1 but independent of treatment. The following regression model was derived for predicting number of days to return to baseline PRU where PI(1) represents platelet percentage inhibition on Washout Day 1. Number days to return to baseline PRU derived from: Number days to return to baseline PRU=-3.350+0.079*PI(1)+0.014*baseline PRU. The predicted number of days to return to baseline based on device-derived platelet percentage inhibition is reported for each treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel 10mg administered for 7 days followed by a Washout Period up to 12 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75mg administered for 7 days followed by a 12 day Washout Period up to 12 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 10mg tablet administered once daily for 7 days.&#xD;
After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria.</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 75 mg tablet administered once daily for 7 days.&#xD;
After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria.</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects &gt;/= 18 years and &lt;75 years of age&#xD;
&#xD;
          -  Weight &gt;/= 60 kg&#xD;
&#xD;
          -  On aspirin therapy (81 mg to 325 mg daily) at the time of screening and able to&#xD;
             maintain a consistent aspirin dosing regimen from the baseline visit through the final&#xD;
             study visit&#xD;
&#xD;
          -  Subjects who do not have contraindications for a thienopyridine (ie, prasugrel,&#xD;
             clopidogrel or ticlopidine), and have a history of stable atherosclerosis represented&#xD;
             by Coronary Artery disease, defined as any of the following:&#xD;
&#xD;
               -  chronic stable angina&#xD;
&#xD;
               -  Prior history of acute coronary syndrome (&gt;/= 30 days before screening) including&#xD;
                  unstable angina or acute myocardial infarction (ST elevation Myocardial&#xD;
                  Infarction [STEMI] or non-ST elevation Myocardial Infarction [NSTEMI]), not&#xD;
                  currently prescribed or currently on thienopyridine therapy;&#xD;
&#xD;
               -  Previous coronary revascularization including percutaneous transluminal coronary&#xD;
                  angioplasty (PTCA), stent, or coronary artery bypass grafting (CABG) coronary&#xD;
                  artery disease (&gt;/= 50% obstruction) in at least one coronary vessel after&#xD;
                  angiography&#xD;
&#xD;
          -  Female subjects who meet one of the following:&#xD;
&#xD;
               -  Women of childbearing potential with a negative serum pregnancy test at screening&#xD;
                  who are not breast feeding, do not plan to become pregnant during the study, and&#xD;
                  agree to use an approved method of birth control during the study. Approved&#xD;
                  methods of birth control are oral, path, injectable or implantable hormonal&#xD;
                  contraception, intrauterine device, diaphragm plus spermicide, or female condom&#xD;
                  plus spermicide. Abstinence, partner's use of condoms, and partner's vasectomy&#xD;
                  are NOT acceptable methods of contraception.&#xD;
&#xD;
               -  Women who have been postmenopausal for at least 1 year or have had a&#xD;
                  hysterectomy, bilateral salpingo-oophorectomy, or tubal ligation at least 6&#xD;
                  months prior to signing the informed consent form.&#xD;
&#xD;
          -  Subjects with a competent mental condition to provide written informed consent before&#xD;
             entering the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other formal indication for the use of a thienopyridine.&#xD;
&#xD;
          -  Subjects with a history of refractory ventricular arrhythmias.&#xD;
&#xD;
          -  Subjects with a history of an implantable defibrillator device.&#xD;
&#xD;
          -  Subjects with a history or evidence of congestive heart failure (New York Heart&#xD;
             Association [NYHA] Class III or above) within 6 months prior to screening.&#xD;
&#xD;
          -  Subjects with significant hypertension (systolic blood pressure &gt;180 mmHg or diastolic&#xD;
             blood pressure &gt;110 mmHg) at either the time of screening or baseline assessment.&#xD;
&#xD;
          -  Bleeding Risk Exclusion Criteria:&#xD;
&#xD;
               -  Any known contraindication to treatment with an anticoagulant or antiplatelet&#xD;
                  agent&#xD;
&#xD;
               -  Prior history or clinical suspicion of cerebral vascular malformations,&#xD;
                  intracranial tumor, transient ischemic attack (TIA), or stroke, or recent history&#xD;
                  (within 3 months) of head trauma&#xD;
&#xD;
               -  Prior history or presence of significant bleeding disorders (eg, hematemesis,&#xD;
                  melena, severe or recurrent epistaxis, hemoptysis, hematuria, or intraocular&#xD;
                  bleeding)&#xD;
&#xD;
               -  History (within the last 5 years) or presence of gastric ulcers. Previous history&#xD;
                  of duodenal ulcer is acceptable but must have been successfully surgically or&#xD;
                  medically treated with no further evidence of disease in the past 6 months (from&#xD;
                  screening).&#xD;
&#xD;
               -  Prior history of abnormal bleeding tendency (ie, prolonged bleeding on dental&#xD;
                  extraction, tonsillectomy, or previous surgical procedure)&#xD;
&#xD;
               -  Known prior history of thrombocytopenia (platelet count &lt; 100,000/mmÂ³) or&#xD;
                  thrombocytosis (platelet count &gt; 500,000/mmÂ³) or recent history (within six&#xD;
                  months) of hemoglobin &lt; 10 mg/dL&#xD;
&#xD;
               -  Clinically significant out of range values for prothrombin time, activated&#xD;
                  partial thromboplastin time (aPTT), platelet count, or hemoglobin at screening,&#xD;
                  in the investigator's opinion&#xD;
&#xD;
               -  History of major surgery, severe trauma, fracture, or organ biopsy within 3&#xD;
                  months prior to enrollment&#xD;
&#xD;
          -  Prior/Concomitant Therapy Exclusion Criteria:&#xD;
&#xD;
               -  Subjects taking prasugrel, clopidogrel, ticlopidine, cilostazol, dipyridamole,&#xD;
                  warfarin, heparin, direct thrombin inhibitors, or glycoprotein IIB/IIIa&#xD;
                  inhibitors =10 days prior to screening or during study participation&#xD;
&#xD;
               -  The use (or planned use) of fibrinolytic agents within 30 days before screening&#xD;
                  or during study participation&#xD;
&#xD;
               -  Subjects receiving treatment with nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
                  or cyclooxygenase-2 (COX-2) inhibitors exceeding 3 doses per week&#xD;
&#xD;
               -  Subjects receiving proton pump inhibitors (PPIs), eg, (lansoprazole,&#xD;
                  esomeprazole, omeprazole, pantoprazole, or rabeprazole) =10 days prior to&#xD;
                  screening or during study participation&#xD;
&#xD;
          -  General Exclusion Criteria:&#xD;
&#xD;
               -  Investigator site personnel directly affiliated with the study or immediate&#xD;
                  family of investigator site personnel directly affiliated with the study.&#xD;
                  Immediate family is defined as a spouse, parent, child, or sibling, whether&#xD;
                  biological or legally adopted&#xD;
&#xD;
               -  Daiichi Sankyo or Eli Lilly employees&#xD;
&#xD;
               -  Currently enrolled in, or discontinued within the last 30 days prior to baseline&#xD;
                  from, a clinical study involving an off-label use of an investigational drug or&#xD;
                  device, or concurrently enrolled in a non-observational clinical study or any&#xD;
                  other type of medical research judged not to be scientifically or medically&#xD;
                  compatible with this study&#xD;
&#xD;
               -  Have previously completed or withdrawn from this study&#xD;
&#xD;
               -  Women who are known to be pregnant and/or who receive a positive serum pregnancy&#xD;
                  test result, who have given birth within the past 90 days, and/or who are&#xD;
                  breastfeeding&#xD;
&#xD;
               -  Results of clinical laboratory tests at the time of screening that are judged to&#xD;
                  be clinically significant for the subject, as determined by the investigator&#xD;
&#xD;
               -  Known allergies or intolerance to aspirin and/or thienopyridines (prasugrel,&#xD;
                  clopidogrel, or ticlopidine)&#xD;
&#xD;
               -  Evidence of significant active neuropsychiatric disease, alcohol abuse or drug&#xD;
                  abuse, in the investigator's opinion&#xD;
&#xD;
               -  Evidence of active hepatic disease, or any of the following; positive human&#xD;
                  immunodeficiency virus (HIV) antibodies, positive hepatitis C antibody, positive&#xD;
                  hepatitis B surface antigen; serum alanine transaminase (ALT), aspartate&#xD;
                  transaminase (AST), or gamma-glutamyltransferase (GGT) &gt;/= 3 times the upper&#xD;
                  limit of normal (ULN) laboratory reference range; or bilirubin &gt;/= 2 times the&#xD;
                  ULN of laboratory reference range at screening&#xD;
&#xD;
               -  Subjects who are unreliable and unwilling to make themselves available for the&#xD;
                  duration of the study and who will not abide by the research unit policy and&#xD;
                  procedure and study restrictions&#xD;
&#xD;
          -  Subjects who have had an angiogram &lt;/= 7 days before randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center Shands Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medpace Clinical Pharmacology Unit</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Clinical Research Center</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <results_first_submitted>May 31, 2011</results_first_submitted>
  <results_first_submitted_qc>August 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2011</results_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thienopyridine</keyword>
  <keyword>pharmacologic action</keyword>
  <keyword>prasugrel</keyword>
  <keyword>clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 4 sites in the US from 23 February 2010 to 24 May 2010 and 56 participants were randomized into the study. The study population consisted of male and female aspirin-treated participants with stable coronary artery disease, 18 to 75 years of age.</recruitment_details>
      <pre_assignment_details>The Overall Study Period included a 1-day to 14-day Screening Period, a 7-day Active Treatment Period, and a Washout Period of up to 12 days. Following the 1-day to 14-day Screening Period, eligible participants were randomized in a 1:1 ratio to either prasugrel or clopidogrel at Visit 2 (the first day of the Active Treatment Period).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prasugrel</title>
          <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout Period up to 12 days.</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel</title>
          <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout Period up to 12 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prasugrel</title>
          <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout Period up to 12 days.</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel</title>
          <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout Period up to 12 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="8.45" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="62.3" spread="8.10" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="59.80" spread="8.56" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.3" spread="15.13" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="90.8" spread="14.41" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="94.1" spread="15.02" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174.1" spread="8.20" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="173.5" spread="9.00" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="173.8" spread="8.52" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="27" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="55" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.0" spread="4.07" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="30.3" spread="5.34" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="31.2" spread="4.76" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="10" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="17" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently Smoke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="6" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="16" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Formerly Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="23" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never used alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="5" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="8" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently use alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="18" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="37" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Formerly used alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="4" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Does not have diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="16" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="34" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Has diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="22" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition of Return to Baseline</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. The results are expressed as cumulative percentage of participants.</description>
        <time_frame>up to 12 days after last dose</time_frame>
        <population>Participants in Primary Population defined as Baseline PRU-PRU less than or equal to 60 units (R-to-B). Primary Population included participants who entered Washout Period and had platelet function data at both baseline and Washout Period Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout period up to 12 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout period up to 12 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition of Return to Baseline</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. The results are expressed as cumulative percentage of participants.</description>
          <population>Participants in Primary Population defined as Baseline PRU-PRU less than or equal to 60 units (R-to-B). Primary Population included participants who entered Washout Period and had platelet function data at both baseline and Washout Period Day 1.</population>
          <units>cumulative percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>return to baseline PRU by washout day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>return to baseline PRU by washout day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>return to baseline PRU by washout day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>return to baseline PRU by washout day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9"/>
                    <measurement group_id="O2" value="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>return to baseline PRU by washout day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                    <measurement group_id="O2" value="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>return to baseline PRU by washout day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Secondary Definition of Return to Baseline</title>
        <description>On the first day of the Washout Period (visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%.</description>
        <time_frame>up to 12 days after last dose</time_frame>
        <population>Participants in Primary Population using secondary definition of return to baseline. Primary Population included participants who entered the Washout Period and had platelet function data at both baseline and Washout Period Day 1. Secondary definition of return to baseline was (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout Period up to 12 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout Period up to 12 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Secondary Definition of Return to Baseline</title>
          <description>On the first day of the Washout Period (visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%.</description>
          <population>Participants in Primary Population using secondary definition of return to baseline. Primary Population included participants who entered the Washout Period and had platelet function data at both baseline and Washout Period Day 1. Secondary definition of return to baseline was (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</population>
          <units>cumulative percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>returned to baseline PRU by washout day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>returned to baseline PRU by washout day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>returned to baseline PRU by washout day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>returned to baseline PRU by washout day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>returned to baseline PRU by washout day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                    <measurement group_id="O2" value="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>returned to baseline PRU by washout day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on Primary Definition of Return to Baseline Using the Primary Population</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participants met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
        <time_frame>up to 12 days after last dose</time_frame>
        <population>Participants in Primary Population using primary definition of return to baseline. Primary population included participants who entered the Washout Period and had platelet function data at both baseline and Washout Period Day 1. Primary definition of return to baseline was (Baseline PRU-PRU) less than or equal to 60 units.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout Period up to 12 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout Period up to 12 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on Primary Definition of Return to Baseline Using the Primary Population</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participants met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
          <population>Participants in Primary Population using primary definition of return to baseline. Primary population included participants who entered the Washout Period and had platelet function data at both baseline and Washout Period Day 1. Primary definition of return to baseline was (Baseline PRU-PRU) less than or equal to 60 units.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Washout day 50% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 75% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 90% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on Secondary Definition of Return to Baseline Using the Primary Population</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
        <time_frame>up to 12 days after last dose</time_frame>
        <population>Participants in Primary Population using secondary definition of return to baseline. Primary Population included participants who entered Washout Period and had platelet function data at both baseline and Washout Period Day 1. Secondary definition of return to baseline was (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout Period up to 12 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout Period up to 12 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on Secondary Definition of Return to Baseline Using the Primary Population</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
          <population>Participants in Primary Population using secondary definition of return to baseline. Primary Population included participants who entered Washout Period and had platelet function data at both baseline and Washout Period Day 1. Secondary definition of return to baseline was (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Washout day 50% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 75% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 90% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on the Primary Definition of Return to Baseline Using the Responder Population</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
        <time_frame>up to 12 days after last dose</time_frame>
        <population>Participants in Responder Population using primary definition of R-to-B. Primary Population included participants who entered Washout Period and had platelet function data at baseline and Washout Day 1. Responder Population was Primary Population excluding poor pharmacodynamic responders. Primary definition of R-to-B was (Baseline PRU-PRU) less than or equal to 60 units.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout Period up to 12 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout Period up to 12 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on the Primary Definition of Return to Baseline Using the Responder Population</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
          <population>Participants in Responder Population using primary definition of R-to-B. Primary Population included participants who entered Washout Period and had platelet function data at baseline and Washout Day 1. Responder Population was Primary Population excluding poor pharmacodynamic responders. Primary definition of R-to-B was (Baseline PRU-PRU) less than or equal to 60 units.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Washout day 50% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 75% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 90% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on the Secondary Definition of Return to Baseline Using the Responder Population</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to (&lt;=) 20%.</description>
        <time_frame>up to 12 days after the last dose</time_frame>
        <population>Participants in Responder Population using secondary definition of R-to-B. Primary Population included participants who entered Washout Period and had platelet function data at both baseline and Washout Period Day 1. Responder Population was Primary Population excluding poor pharmacodynamic responders. Secondary definition of R-to-B was (Baseline PRU-PRU)/ (Baseline PRU) &lt;= 20%.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout Period up to 12 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout Period up to 12 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Day at Which 50%, 75%, and 90% of Participants Returned to Baseline Platelet Function Based on the Secondary Definition of Return to Baseline Using the Responder Population</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to (&lt;=) 20%.</description>
          <population>Participants in Responder Population using secondary definition of R-to-B. Primary Population included participants who entered Washout Period and had platelet function data at both baseline and Washout Period Day 1. Responder Population was Primary Population excluding poor pharmacodynamic responders. Secondary definition of R-to-B was (Baseline PRU-PRU)/ (Baseline PRU) &lt;= 20%.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Washout day 50% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 75% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 90% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Inhibition of Platelet Aggregation on Washout Day 1</title>
        <description>Inhibition of platelet aggregation was assessed by Accumetrics VerifyNowÂ® P2Y12 reaction units (PRU). On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%.</description>
        <time_frame>Washout Day 1</time_frame>
        <population>Participants in the Primary Population. The Primary Population included participants who entered the Washout Period and had platelet function testing data at both baseline (Visit 2) and Washout Period Day 1 (Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout Period up to 12 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout Period up to 12 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Inhibition of Platelet Aggregation on Washout Day 1</title>
          <description>Inhibition of platelet aggregation was assessed by Accumetrics VerifyNowÂ® P2Y12 reaction units (PRU). On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%.</description>
          <population>Participants in the Primary Population. The Primary Population included participants who entered the Washout Period and had platelet function testing data at both baseline (Visit 2) and Washout Period Day 1 (Visit 3).</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" spread="11.78"/>
                    <measurement group_id="O2" value="35.4" spread="23.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Baseline PRU for the Primary Population Using the Primary Definition of Return to Baseline in Relation to the Inhibition of Platelet Aggregation 24 Hours Following the Last Maintenance Dose</title>
        <description>Time to return to baseline PRU (&lt;= 60 units of baseline) dependent upon baseline PRU and platelet % inhibition on Washout Period Day 1 but independent of treatment. The following regression model was derived for predicting number of days to return to baseline PRU where PI(1) represents platelet percentage inhibition on Washout Day 1. Number days to return to baseline PRU derived from: Number days to return to baseline PRU=-3.350+0.079*PI(1)+0.014*baseline PRU. The predicted number of days to return to baseline based on device-derived platelet percentage inhibition is reported for each treatment group.</description>
        <time_frame>up to 12 days after the last dose</time_frame>
        <population>Participants in the Primary Population. The Primary Population included participants who entered the Washout Period and had platelet function testing data at both baseline (Visit 2) and Washout Period Day 1 (Visit 3). The primary definition of return to baseline was (Baseline PRU-PRU) less than or equal to 60 units.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout Period up to 12 days.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout Period up to 12 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Baseline PRU for the Primary Population Using the Primary Definition of Return to Baseline in Relation to the Inhibition of Platelet Aggregation 24 Hours Following the Last Maintenance Dose</title>
          <description>Time to return to baseline PRU (&lt;= 60 units of baseline) dependent upon baseline PRU and platelet % inhibition on Washout Period Day 1 but independent of treatment. The following regression model was derived for predicting number of days to return to baseline PRU where PI(1) represents platelet percentage inhibition on Washout Day 1. Number days to return to baseline PRU derived from: Number days to return to baseline PRU=-3.350+0.079*PI(1)+0.014*baseline PRU. The predicted number of days to return to baseline based on device-derived platelet percentage inhibition is reported for each treatment group.</description>
          <population>Participants in the Primary Population. The Primary Population included participants who entered the Washout Period and had platelet function testing data at both baseline (Visit 2) and Washout Period Day 1 (Visit 3). The primary definition of return to baseline was (Baseline PRU-PRU) less than or equal to 60 units.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Beginning with screening, adverse events (AEs) were assessed at every visit. All AEs occuring after participant signed informed consent and up to 14 days after last dose of study drug were recorded</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prasugrel</title>
          <description>Prasugrel 10mg tablet administered once daily for 7 days followed by a Washout Period up to 12 days.</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel</title>
          <description>Clopidogrel 75 mg tablet administered once daily for 7 days followed by Washout Period up to 12 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>eyelid oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Adominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>increased tendency to bruise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Baker</name_or_title>
      <organization>Daiichi Sankyo, Inc.</organization>
      <phone>973-944-2712</phone>
      <email>bbaker@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

